Abstract
Right ventricular (RV) function is the strongest predictor of survival in age-related heart failure as well as other clinical contexts in which aging populations suffer significant morbidity and mortality. However, despite the significance of maintaining RV function with age and disease, mechanisms of RV failure remain poorly understood and no RV-directed therapies exist. The anti-diabetic drug and AMP-activated protein kinase (AMPK) activator metformin protects against left ventricular dysfunction, suggesting cardioprotective properties may translate to the RV. Here, we aimed to understand the impact of advanced age on pulmonary hypertension induced right ventricular dysfunction. We further aimed to test whether metformin is cardioprotective in the RV and if the protection afforded by metformin requires cardiac AMPK. We used a murine model of PH by exposing adult (4-6 months) and aged (18 months) male and female mice to hypobaric hypoxia (HH) for 4 weeks. Cardiopulmonary remodeling was exacerbated in aged mice compared to adult as evidenced by elevated RV weight and impaired RV systolic function. Metformin attenuated HH induced RV dysfunction but only in adult male mice. Metformin still protected the adult male RV even in the absence of cardiac AMPK. Together, we suggest that aging exacerbates PH-induced RV remodeling and that metformin may represent a therapeutic option for this disease in a sex and age-dependent, but in an AMPK independent manner. Ongoing efforts are aimed at elucidating the molecular basis for RV remodeling as well as delineating the mechanisms of cardioprotection provided by metformin in the absence of cardiac AMPK.
Full text
